Data on Chronic Myeloid Leukemia Discussed by Researchers at Zunyi Medical University (Mitochondrial Complex I Inhibition By Homoharringtonine: a Novel Strategy for Suppression of Chronic Myeloid Leukemia).

Researchers at Zunyi Medical University in Zhuhai, China have conducted a study on chronic myeloid leukemia (CML), a type of blood cancer driven by the BCR-ABL fusion gene. The study focused on the effectiveness of the FDA-approved drug Homoharringtonine (HHT) in treating CML, particularly in cases with the T315I mutation that is resistant to tyrosine kinase inhibitors (TKIs). The researchers found that HHT demonstrated significant anti-CML effects by inhibiting mitochondrial complex I (MCI) and disrupting oxidative phosphorylation (OXPHOS). This study provides insights into a novel therapeutic strategy for overcoming resistance to TKIs in CML treatment. [Extracted from the article]

Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)